Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.01
0.020.33%
At close: -
$6.00
-0.01000-0.17%
After Hours: May 16, 4:00 PM EDT
Comments
Loading...
Abivax Analyst Ratings and Price Targets | NASDAQ:ABVX | Benzinga
Abivax SA has a consensus price target of $33 based on the ratings of 10 analysts. The high is $50 issued by Guggenheim on April 29, 2024. The low is $12 issued by Morgan Stanley on March 20, 2025. The 3 most-recent analyst ratings were released by JMP Securities, Morgan Stanley, and Citizens Capital Markets on April 30, 2025, March 20, 2025, and March 18, 2025, respectively. With an average price target of $26 between JMP Securities, Morgan Stanley, and Citizens Capital Markets, there's an implied 333.33% upside for Abivax SA from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Morgan Stanley
Citizens Capital Markets
JMP Securities
Laidlaw & Co.
1calculated from analyst ratings
Analyst Ratings for Abivax
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/30/2025 | Buy Now | 450% | JMP Securities | Jason Butler49% | $33 → $33 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/20/2025 | Buy Now | 100% | Morgan Stanley | Judah Frommer65% | → $12 | Assumes | → Equal-Weight | Get Alert |
| 03/18/2025 | Buy Now | 450% | Citizens Capital Markets | Jason Butler49% | $33 → $33 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/10/2025 | Buy Now | 450% | JMP Securities | Roy Buchanan34% | $33 → $33 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/04/2024 | Buy Now | 450% | JMP Securities | Jason Butler49% | → $33 | Initiates | → Market Outperform | Get Alert |
| 07/29/2024 | Buy Now | 700% | Laidlaw & Co. | Yale Jen22% | → $48 | Initiates | → Buy | Get Alert |
| 05/20/2024 | Buy Now | 616.67% | BTIG | Julian Harrison38% | → $43 | Initiates | → Buy | Get Alert |
| 04/29/2024 | Buy Now | 733.33% | Guggenheim | Yatin Suneja47% | → $50 | Initiates | → Buy | Get Alert |
| 04/29/2024 | Buy Now | 600% | Piper Sandler | Christopher Raymond53% | → $42 | Initiates | → Overweight | Get Alert |
| 04/11/2024 | Buy Now | 166.67% | Morgan Stanley | Vikram Purohit37% | $15 → $16 | Maintains | Equal-Weight | Get Alert |
| 11/14/2023 | Buy Now | 233.33% | Leerink Partners | Thomas Smith33% | → $20 | Initiates | → Outperform | Get Alert |
| 11/14/2023 | Buy Now | 150% | Morgan Stanley | Vikram Purohit37% | → $15 | Initiates | → Equal-Weight | Get Alert |
FAQ
What is the target price for Abivax (ABVX) stock?
The latest price target for Abivax (NASDAQ:ABVX) was reported by JMP Securities on April 30, 2025. The analyst firm set a price target for $33.00 expecting ABVX to rise to within 12 months (a possible 450.00% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abivax (ABVX)?
The latest analyst rating for Abivax (NASDAQ:ABVX) was provided by JMP Securities, and Abivax reiterated their market outperform rating.
When was the last upgrade for Abivax (ABVX)?
There is no last upgrade for Abivax
When was the last downgrade for Abivax (ABVX)?
There is no last downgrade for Abivax.
When is the next analyst rating going to be posted or updated for Abivax (ABVX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abivax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abivax was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.
Is the Analyst Rating Abivax (ABVX) correct?
While ratings are subjective and will change, the latest Abivax (ABVX) rating was a reiterated with a price target of $33.00 to $33.00. The current price Abivax (ABVX) is trading at is $6.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
